๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer

โœ Scribed by Joseph C. Allegra; Thomas M. Woodcock; Stephen P. Richman; Kirby I. Bland; James L. Wittliff

Publisher
Springer US
Year
1982
Tongue
English
Weight
773 KB
Volume
2
Category
Article
ISSN
0167-6806

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Methotrexate, vinblastine, doxorubicin,
Methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic breast cancer. A phase II trial of the hoosier oncology group
โœ Bruce J. Roth; George W. Sledge Jr; Stephen D. Williams; Steven C. Meyer; Rafat ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 490 KB ๐Ÿ‘ 2 views

Forty-six eligible patients with metastatic breast cancer (MBC) were treated with a combination of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) as first-line chemotherapy. Of 44 patients evaluable for response, 28 (64%) had an objective response, including seven (16%) who had a comp

Phase II trial of carboplatin and etopos
Phase II trial of carboplatin and etoposide in metastatic breast cancer
โœ John Crown; Thomas Hakes; Bonnie Reichman; David Lebwohl; Theresa Gilewski; Anto ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 345 KB ๐Ÿ‘ 2 views

## Background: High-dose chemotherapy with hematopoietic support produces high rates of response in metastatic breast cancer. to facilitate new high-dose regimens there is a need to identify active agents with toxicity limited to hematopoietic suppression. cisplatin/etoposide is a highly active reg